Veranova A CDMO that manages complexity with confidence

Veranova A CDMO that manages complexity with confidence

X

Find Clinical Drug Pipeline Developments & Deals by Avista Therapeutics

Avista Therapeutics

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

No Presentations

VIDEO(s)

No Video

DIGITAL CONTENT

1 News

1 News

DEVELOPMENTS

1 Drug(s) in Development

1 Drug(s) in Development

Developments

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Therapeutic Area

filter

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

Avista Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseases

Details:

The partnership aims to apply Avista’s single-cell adeno-associated virus (AAV) engineering (scAAVengr) platform technology to develop intravitreal AAV capsids matching a capsid profile defined by Roche.

Lead Product(s): AAV-based Gene Therapy

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

Deal Size: $1,007.5 million Upfront Cash: $7.5 million

Deal Type: Partnership July 19, 2022

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY